clinical trails model uploaded.... : D

README.md

@@ -1,3 +1,898 @@
 ---
-license: apache-2.0
+tags:
+- sentence-transformers
+- sentence-similarity
+- feature-extraction
+- generated_from_trainer
+- dataset_size:92934
+- loss:MatryoshkaLoss
+- loss:MultipleNegativesRankingLoss
+base_model: sentence-transformers/all-MiniLM-L6-v2
+widget:
+- source_sentence: aprepitant prevention chemotherapy induce nausea vomit cinv0869130complete.
+    The purpose of this study is to assess the efficacy and safety of recombinant
+    human tissue plasminogen kinase derivatives for injection and alteplase in the
+    treatment of patients with acute ischemic stroke within 4.5 hours.
+  sentences:
+  - Coronary Artery Diseases|Multivessel Coronary Artery Disease|Heart Diseases|Cardiovascular
+    Diseases inclusion criteria1 patient 1 stenosis angiographic visually determine
+    de novo lesion 50 d 3 major epicardial territory lad andor branch cx andor branch
+    rca andor branch supply viable myocardium left main involvement2 patient hypoplastic
+    rca absence descend posterior presence lesion lad cx territory include trial 3vd
+    equivalent3 vessel size 15 mm diameter visually assess diagnostic angiogram4 patient
+    chronic stable angina stabilize acute coronary syndrome inclusion criterion syntax
+    study     stable canadian cardiovascular society class 1 2 3 4 angina pectoris    unstable
+    braunwald class ib ic iib iic iiib iiic angina pectoris ischemia normal cardiac
+    enzyme value prior enrollment    patient atypical chest pain asymptomatic provide
+    myocardial ischemia eg treadmill exercise test radionuclide scintigraphy stress
+    echocardiography5 anatomical syntax score eligible6 patient amenable msct coronary
+    angiography eg claustrophobia high heartrate amenable betablocker poor renal function
+    etc discretion investigator7 patient inform nature study agree provision provide
+    write informed consent approve ethical committee respective clinical siteexclusion
+    criteria1 age 18 years2 unable informed consent3 know pregnancy time enrolment
+    female childbeare potential menstruation 12 month take adequate contraceptive
+    female breastfeed time enrolment4 prior pci cabg history coronary stent implantation5
+    evidence evolve ongoing acute myocardial infarction ami ecg andor elevated cardiac
+    biomarker accord local standard hospital practice return normal limit time enrollment6
+    concomitant cardiac valve disease require surgical therapy reconstruction replacement7
+    single twovessel disease time heart team consensus8 atrial fibrillation significant
+    arrhythmias9 know allergy iodinate contrast10 body mass index bmi 35 greater11
+    participation trial investigational drug device interrater agreement revascularization
+    strategy heart team angiofirst algorithm ct algorithm interrater agreement assess
+    cohens kappa kappa revascularization strategy heart team angiofirst algorithm
+    base invasive syntax score ii ctfirst algorithm base noninvasive syntax score
+    ii ffrct 95 confidence interval ci heart team meeting take place average 1 2 week
+    afer patient enrollment level agreement decision make strategy base ct functional
+    assessment decision make strategy base ct functional assessment ct algorithm group
+    screen analysis nov 2017level agreement decision make strategy base ct functional
+    assessment decision make strategy base ct functional assessment conventional angiography
+    ct algorithm group screen analysis nov 2017level agreement decision make strategy
+    base conventional angiography decision make strategy base ct functional assessment
+    conventional angiography angio algorithm group screen analysis nov 2017interrater
+    agreement revascularization strategy base conventional angiography ct functional
+    assessment heart team angiofirst algorithm ctfirst algorithm screen analysis nov
+    2017anatomical syntax score calculation base noninvasive ge revolution ct visual
+    heart team involve experienced coronary ct reader result syntax score ii screen
+    analysis nov 2017anatomical syntax score calculation base noninvasive ge revolution
+    ct visual core lab result syntax score ii screen analysis nov 2017anatomical syntax
+    score calculation base invasive angiography visual heart team result syntax score
+    ii screen analysis nov 2017anatomical syntax score calculation base invasive angiography
+    visual core lab result syntax score ii screen analysis nov 2017ct base functional
+    anatomy ffrct assess heartflow screen analysis nov 2017concordance syntax score
+    strategy screen analysis nov 2017agreement coronary stenosis segment revascularize
+    strategy screen analysis nov 2017
+  - 'HIV Infections inclusion criterion 20 20 ideal weight height estimate frame size
+    good health clinically significant abnormal finding physical examination medical
+    history laboratory testsexclusion criterion history clinically significant disease
+    history clinically significant allergy include drug allergy participate clinical
+    trial 3 month prior study entry hiv infect hepatitis b c virus infect active significant
+    infection prior exposure allergy know hypersensitivity pro 140 safety tolerability
+    pro 140 60 day '
+  - "Chemotherapy-Induced Nausea and Vomiting inclusion criterion patient naive emetogenic\
+    \ chemotherapy histologically cytologically confirm malignant disease schedule\
+    \ receive single dose moderately emetogenic chemotherapy study day 1 karnofsky\
+    \ score 60 greaterexclusion criterion patient schedule receive dose cisplatin\
+    \ patient receive abdominal pelvic radiation week prior 6 day initiation chemotherapy\
+    \ allergy study drug antiemetic take cyp3a4 substratesprohibite medication significant\
+    \ medical mental condition abnormal laboratory value platelet absolute neutrophil\
+    \ ast alt bilirubin creatinine number patient report vomiting number patient report\
+    \ vomiting overall phase cycle \n\n 1 overall phase 0120 hour post initiation\
+    \ mec cycle 1 number patient report complete response number patient report complete\
+    \ response vomiting use rescue medication overall phase cycle 1 overall phase\
+    \ 0120 hour post initiation mec cycle 1"
+- source_sentence: eribulin mesylate phase iv clinical trial korean patient metastatic
+    locally advanced breast cancer. This study will treat patients with Metastatic
+    Castration Resistant Prostate Cancer who have progressed following prior therapy.
+    This is the first time this drug has ever been tested in patients, and so it will
+    help to understand what type of side effects may occur with the drug treatment.
+    It will also measure the the levels of drug in the body and preliminarily assess
+    its anti-cancer activity as monotherapy.
+  sentences:
+  - End Stage Renal Disease inclusion criterion esrd patient age 18   80 year clinically
+    stable judge treat physician 30 day prior enrollment demonstrate pertinent patient
+    medical history physical examination laboratory testing hemodialysis therapy hdf
+    3 month immediately prior study enrollmentexclusion criterion inform consent provide
+    significant psychiatric disorder mental disability condition interfere patient
+    ability provide informed consent pregnant breastfeeding planning pregnant unstable
+    vascular access associate risk low variable extracorporeal blood flow rate qb
+    chronic liver disease know paraproteinassociate disease know bleed disorder eg
+    gastrointestinal bleed colonic polyp small bowel angiodysplasia active peptic
+    ulcer major bleeding episode ie soft tissue bleed blood stool joint damage retinal
+    bleed extensive mucosal bleed exsanguination cerebral hemorrhage   12 week prior
+    enrollment blood red blood cell transfusion   12 week prior enrollment clinical
+    sign acute infection   4 week prior enrollment active cancer basal cell squamous
+    cell skin cancer positive serology test human immunodeficiency virus hepatitis
+    infection schedule plan intervention require hospitalization   1 week schedule
+    livingdonor transplantation study period currently participate interventional
+    clinical study participate interventional clinical study past 3 month interfere
+    study reduction ratio lambda immunoglobulin free light chain λflc week 12reduction
+    ratio kappa immunoglobulin free light chain kflc week 12reduction ratio chitinase3like
+    protein 1 ykl40 week 12reduction ratio fibroblast growth factor 23 fgf23 week
+    12reduction ratio serum beta2 microglobulin β2 m week 12 change baseline midweek
+    predialysis serum level λflc κflc ykl40 fgf23 ß2 m week 12 24change baseline midweek
+    predialysis serum level pentraxin3 ptx3 high sensitivity creactive protein hscrp
+    interleukin il6 interleukin10 il10 week 12 24percent change pre postdialysis midweek
+    serum level hscrp week 12percent change pre postdialysis midweek serum level ptx3
+    week 12percent change pre postdialysis midweek serum level il6 week 12percent
+    change pre postdialysis midweek serum level il10 week 12change baseline midweek
+    predialysis serum level fibrinogen week 12 24change baseline midweek predialysis
+    serum level albumin week 12 24single pool ktvurea week 24serum phosphorous week
+    24kidney disease quality life 36 kdqol36 baseline week 12 week 24dialysis symptom
+    index dsi baseline week 12 week 24serum ferritin baseline week 12 week 24transferrin
+    saturation tsat baseline week 12 week 2424hour urine output monthly basis month
+    1 month 2 month 3 month 4 month 5 month 6erythropoiesis stimulate agent esa responsiveness
+    baseline week 4 week 8 week 12 week 16 week 20 week 24hemoglobin level baseline
+    week 4 week 8 week 12 week 16 week 20 week 24esa dosage type administration frequency
+    route baseline week 4 week 8 week 12 week 16 week 20 week 24intravenous iron dosage
+    baseline week 4 week 8 week 12 week 16 week 20 week 24number adverse event hospitalization
+    cardiovascular event infective episode week 1 week 24total patient death week
+    1 week 24
+  - Skin Laxity inclusion criterion male female subject age 18   75 year old asa physical
+    status classification system class class ii subject complaint skin laxity line
+    low eyelid area understand accept obligation undergo procedure treatment area
+    treat study participation absence physical condition unacceptable investigator
+    female childbeare potential sexually active willing use approve method birth control
+    study participation willing able comply protocol requirement include studyrequired
+    imagesphotos assessmentsmeasurement return followup visit willing release right
+    use study photo include publication able read understand sign date inform consent
+    able communicate site video andor photograph event virtual followup visitexclusion
+    criterion subject present asa physical status classification system class iii
+    high festoon periorbital area prior cosmeticaesthetic filler hyaluronic acid polyllactic
+    acid calcium hydroxylapatite et study treatment area past 12 month pregnant lactating
+    plan pregnant study participation know hypersensitivity allergy tumescent anesthetic
+    lidocaine epinephrine know hypersensitivity allergy ibuprofen nsaid previous surgery
+    study treatment area active systemic local skin disease alter wound heal significant
+    uncontrolled medical condition opinion investigator participation study compromise
+    patient health history autoimmune disease exclude hashimotos thyroiditis know
+    susceptibility keloid formation hypertrophic scar cancerous precancerous lesion
+    area treat possess surgically implant electronic device ie pacemaker mental health
+    illness dementia schizophrenia psychiatric hospitalization past year participation
+    investigational study 30 day prior consent study participation subject opinion
+    investigator appropriate candidate study day 180 number participant improvement
+    low eyelid area determine mask qualitative assessment improvement low eyelid area
+    determine mask qualitative assessment photograph 180days posttreatment compare
+    baseline blind independent reviewer improvement assess base photograph take visit
+    site 2d camera system 180day day 90 number participant improvement low eyelid
+    area determine mask qualitative assessment improvement low eyelid area determine
+    mask qualitative assessment photograph 90days posttreatment compare baseline blind
+    independent reviewer improvement assess base photograph take visit site 2d camera
+    system 90day
+  - Breast Neoplasms|Breast Cancer inclusion criteria1 female age great equal 20 years2
+    patient histologically cytologically confirm carcinoma breast3 patient locally
+    advance metastatic carcinoma breast4 patient receive prior chemotherapeutic regimen
+    include antracycline taxane 2 regimen locally recurrent andor metastatic disease5
+    patient prove refractory recent chemotherapy 6 month therapy6 patient assessable
+    lesion accord recist v 117 adequately maintain bone marrow function     absolute
+    neutrophil count anc great equal 15 x 109 l    hemoglobin great equal 100 gdl
+    hemoglobin 100 gdl acceptable correct erythropoietin transfusion    platelet count
+    great equal 100 x 109 l8 adequately maintain liver function     total bilirubin
+    equal 15 time upper limit normal uln    alkaline phosphatasealp alanine aminotransferase
+    alt aspartate aminotransferase ast equal 3 x uln case liver metastasis equal 5
+    x uln9 adequately maintain renal function     serum creatinine equal 20 mgdl    calculate
+    creatinine clearance great equal 40 mlmin cockcroft gault formula10 resolution
+    chemotherapy radiationrelated toxicity grade 1 severity low      alopecia     stable
+    sensory neuropathy equal grade 211 eastern cooperative oncology group ecog performance
+    status 0 212 life expectancy great equal 3 months13 patient willing able comply
+    study protocol duration study14 patient provide write consent participate studyexclusion
+    criteria1 patient receive chemotherapy radiation biologic immunotherapy hormonal
+    therapy week treatment start palliative radiation enrolled2 pulmonary lymphangitic
+    involvement result pulmonary dysfunction require active treatment include use
+    oxygen3 patient brain subdural metastasis eligible complete local therapy discontinue
+    use corticosteroid indication week start treatment study sign andor symptom brain
+    metastasis stable week start study treatment4 patient meningeal carcinomatosis5
+    significant cardiovascular impairment     myocardial infarction past month unstable
+    angina history congestive heart failure nyha class iii iv cardiac arrhythmia    qtc
+    prolongation bazetts formula great 480 msec congenital long qt syndrome6 severeuncontrolle
+    intercurrent illnessinfection require administration antibiotic injection7 patient
+    process major surgery week participation clinical trial8 patient prior malignancy
+    past year breast cancer treat nonmelanoma skin cancer carcinoma situ cervix excluded9
+    patient know positive hiv status10 patient receive genetic therapy investigational
+    drug 4 week treatment start expect receive prohibit medication11 patient prior
+    allergy halichondrin b derivative active ingredient diluting agent12 patient receive
+    investigational product registration study13 patient pregnant possibly pregnant
+    lactating14 patient agree practice contraception study periods15 patient participate
+    clinical trial 4 week screening16 patient judge investigator sub investigator
+    unsuitable inclusion number participant treatmentemergent adverse event teae treatmentemergent
+    adverse event sae ae define harmful untoward sign include abnormal laboratory
+    value etc symptom disease participant administer investigational product necessarily
+    causal relationship treatment sae define ae life threaten result death result
+    hospitalization initial prolonged result disability significant persistent permanent
+    change impairment damage disruption participant body functionstructure physical
+    activity quality life result congenital anomaly require intervention prevent permanent
+    impairment damage teaes define event start date time administration dose study
+    drug event present prior administration dose study drug increase severity study
+    mean 376 month disease control rate dcr dcr define number participant complete
+    response cr partial response pr stable disease sd response evaluation criterion
+    solid tumor recist version 11 assess tumor response tumor response evaluate investigator
+    cr define disappearance extranodal target lesion pathological lymph node decrease
+    10 millimeter mm short axis pr define 30 decrease sum long diameter sld target
+    lesion take reference baseline sum diameter sd define sufficient shrinkage qualify
+    pr sufficient increase qualify progressive disease sld increase 20 small value
+    study include baseline small sld demonstrate absolute increase 5 mm lesion increase
+    2 mm 3 mm example qualify mean 376 month
+- source_sentence: 'safety study mt4666 subject alzheimer disease. This is a phase
+    1, randomized, open label, single-dose, replicate crossover clinical trial to
+    compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.
+
+
+    Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.'
+  sentences:
+  - Alzheimer's Disease inclusion criterion probable alzheimer disease consistent
+    national institute aging alzheimers association criterion diagnosis alzheimer
+    disease mckhann et al 2011 mmse score   14   24 screening   12   26 baseline modify
+    hachinski ischemic score mhis   4 screening appropriate caregiver available subject
+    live home facility require continuous 24hour nursing careexclusion criterion diagnosis
+    disease cause dementia diagnosis major depressive disorder define diagnostic statistical
+    manual mental disorder fourth edition text revision dsmivtr year history current
+    diagnosis psychosis history myocardial infarction unstable angina month screen
+    history cerebrovascular disorder 18 month screen complication hepatic disorder
+    renal dysfunction safety 2 fix dose evp6124 subject alzheimer disease criterion
+    evaluation include adverse event clinical laboratory test vital sign body weight
+    12lead ecg columbia suicide severity rating scale cssrs week 56 change mini mental
+    state examination mmse baseline week 52change neuropsychiatric inventory npi total
+    score baseline week 52
+  - 'Type 2 Diabetes inclusion criteria1 man nonpregnant woman 2865 year age2 diagnose
+    t2d 3 years3 a1c 75   95 5980 mmolmol4 bmi   28   40 kgm25 oral oad metformin
+    plus additional oad note half maximum label dose high tolerate change medication
+    12 week prior screening visit visit 1 refer ada standard medical care diabetes
+    2018 table 83 maximum approve daily dose noninsulin glucose lower agent 43 note
+    subject sulfonylurea su glucoselowere drug diabetes sus permit study glipizide
+    glimepiride dose half maximum label dosing exclusion study entry patient unwilling
+    reduce dose su time dmr procedure describe protocol excluded6 agree use additional
+    glucoselowere treatment eg liraglutide oad exception glyburide recommend study
+    investigator case persistent hyperglycemia7 agree donate blood participation study8
+    able comply study requirement understand sign inform consent form9 woman childbeare
+    potential wocbp acceptable method contraception study10 woman breastfeedingexclusion
+    criteria1 diagnose type 1 diabetes t1d2 history diabetic ketoacidosis hyperosmolar
+    nonketotic coma3 probable insulin production failure define fast c peptide serum
+    1 ngml 333pmoll4 previous use type insulin 1 month time treatment gestational
+    diabetes5 current use injectable medication diabetes insulin glp1ra6 current use
+    glyburide sulfonylurea su glucoselowere drug diabetes7 hypoglycemia unawareness
+    history severe hypoglycemia 1 severe hypoglycemic event define need thirdpartyassistance
+    year8 know autoimmune disease include limit celiac disease preexist symptom systemic
+    lupus erythematosus scleroderma autoimmune connective tissue disorder9 previous
+    gi surgery limit treatment duodenum bilroth 2 rouxeny gastric bypass similar procedure
+    conditions10 history chronic acute pancreatitis11 history diabetic gastroparesis12
+    know active hepatitis active liver disease13 acute gastrointestinal illness previous
+    7 days14 know history irritable bowel syndrome radiation enteritis inflammatory
+    bowel disease crohns disease15 know history structural functional disorder esophagus
+    impede passage device gastrointestinal tract increase risk esophageal damage endoscopic
+    procedure include barretts esophagus esophagitis dysphagia achalasia stricturestenosis
+    esophageal varix esophageal diverticula esophageal perforation disorder esophagus16
+    know history structural functional disorder esophagus include swallowing disorder
+    esophageal chest pain disorder drug refractory esophageal reflux symptoms17 know
+    history structural functional disorder stomach include gastroparesis gastric ulcer
+    chronic gastritis gastric varix hiatal hernia   2 cm cancer disorder stomach18
+    know history chronic symptom suggestive structural functional disorder stomach
+    include symptom chronic upper abdominal pain chronic nausea chronic vomiting chronic
+    dyspepsia symptom suggestive gastroparesis include postprandial fullness pain
+    postprandial nausea vomiting early satiety19 know history duodenal ulcer intestinal
+    diverticula diverticulitis intestinal varix intestinal stricturestenosis small
+    bowel obstruction obstructive disorder gi tract20 currently ongoing symptom suggestive
+    intermittent small bowel obstruction recurrent bout postprandial abdominal pain
+    nausea vomiting21 active h pylori infection subject active h pylori continue screening
+    process treat appropriate antibiotic regimen22 history coagulopathy upper gastrointestinal
+    bleeding condition ulcer gastric varix stricture congenital acquire intestinal
+    telangiectasia23 current use anticoagulation therapy warfarin discontinue 7 day
+    14 day procedure24 current use p2y12 inhibitor clopidogrel pasugrel ticagrelor
+    discontinue 14 day 14 day procedure25 unable discontinue nonsteroidal antiinflammatory
+    drug nsaid treatment 4 week follow procedure use low dose aspirin allowed26 current
+    use serotonergic medication ssri27 use systemic glucocorticoid exclude topical
+    ophthalmic application inhale form 10 consecutive day 90 day prior screening visit28
+    use drug know affect gi motility eg metoclopramide29 receive weight loss medication
+    meridia xenical counter weight loss medications30 untreatedinadequately treat
+    hypothyroidism define elevated thyroidstimulating hormone tsh level screen thyroid
+    hormone replacement therapy stable dose 6 week prior screening31 persistent anemia
+    define hemoglobin 10 gdl32 subject donate blood receive transfusion prior 3 months33
+    subject condition alter red blood cell turnover34 subject prosthetic joints35
+    significant cardiovascular disease include know history valvular disease myocardial
+    infarction heart failure transient ischemic attack stroke 6 months36 moderate
+    severe chronic kidney disease ckd estimate glomerular filtration rate egfr 45
+    mlmin173m2 estimate mdrd37 know immunocompromise status include limit individual
+    undergo organ transplantation chemotherapy radiotherapy past 12 month clinicallysignificant
+    leukopenia positive human immunodeficiency virus hiv immune status make subject
+    poor candidate clinical trial participation opinion investigator38 active systemic
+    infection39 active malignancy 5 year exception treat basal cell treat squamous
+    cell carcinoma40 subject personal family history medullary thyroid carcinoma41
+    subject multiple endocrine neoplasia syndrome type 242 candidate surgery general
+    anesthesia43 active illicit substance abuse alcoholism44 current smoker45 participate
+    ongoing clinical trial investigational drug device46 mental physical condition
+    opinion investigator make subject poor candidate clinical trial participation47
+    unwilling unable perform smbg complete patient diary comply study visit study
+    procedure require protocoladditional exclusion criterion confirm screening process1
+    a1c post runin phase   75 59 mmolmol   95 86 mmolmol2 severe hypoglycemic event
+    define hypoglycemia require thirdparty assistance clinically significant hypoglycemic
+    event define selfmonitored laboratory plasma glucose level   54 mgdl 30 mmoll   2
+    glucose alert value 70 mgdl 39 mmoll clear correctable precipitating factor identify
+    screening visit visit 13 uncontrolled hyperglycemia glucose level 270 mgdl 15
+    mmoll overnight fast 360 mgdl 20 mmoll randomly perform measurement medication
+    runin period confirm second measurement day4 mean 3 separate blood pressure measurement
+    180 mmhg systolic 100 mmhg diastolic5 wocbp positive urine pregnancy test baseline
+    visit6 active uncontrolled gerd define grade iii esophagitis greater7 abnormality
+    gi tract prevent endoscopic access duodenum8 anatomic abnormality duodenum preclude
+    completion dmr procedure include tortuous anatomy9 malignancy newly diagnose endoscopy10
+    upper gastrointestinal condition ulcer polyp varix stricture congenital acquire
+    intestinal telangiectasia change hemoglobin a1c hba1c change hba1c baseline dmr
+    vs sham group 24 week post procedure '
+  - Solid Tumors inclusion criteria1 male female age   18 years2 histologically cytologically
+    confirm nonhematologic malignancy3 eastern cooperative oncology group ecog performance
+    score 024 adequate bone marrow renal hepatic function follow     bone marrow absolute
+    neutrophil count anc   1500mm3 platelet   100000mm3   hemoglobin   90 gdl    renal
+    function serum creatinine   20 mgdl    hepatic function ast alt   15 x uln liver
+    metastasis present ast alt   50 x uln bilirubin   15 mgdl5 ptt   15 x uln andor
+    inr   156 woman childbeare potential man agree use adequate contraception follow
+    list prior study entry duration study participation 90 day follow completion therapy
+    woman childbeare potential negative urine pregnancy test 7 day prior initiation
+    treatment andor post menopausal woman amenorrheic 12 month consider nonchildbeare
+    potential     total abstinence sexual intercourse minimum complete menstrual cycle    vasectomize
+    male subject vasectomized partner female subject    hormonal contraceptive oral
+    parenteral transdermal 3 month prior study drug administration subject currently
+    hormonal contraceptive use barrier method study 1 month study completion    intrauterine
+    device iud    double barrier method condom contraceptive sponge diaphragm vaginal
+    ring spermicidal jelly cream    additionally male subject include vasectomize
+    partner pregnant pregnant agree use condom duration study 90 day follow completion
+    therapy7 capable understanding comply parameter outline protocol able sign inform
+    consent approve independent ethic committee iecinstitutional review board irb
+    prior initiation screening studyspecific proceduresexclusion criteria1 receive
+    anticancer therapy include investigational agent cytotoxic chemotherapy radiation
+    therapy biologic therapy 21 day period define 5 half life whichever short prior
+    study drug administration addition subject recover equal grade 1 clinically significant
+    adverse effectstoxicitie previous therapy2 undergo major surgery 21 day study
+    day 13 untreated brain meningeal metastasis subject treat brain metastasis radiographically
+    clinically stable 4 week therapy evidence cavitation hemorrhage brain lesion eligible
+    provide asymptomatic require corticosteroid discontinue steroid 1 week prior study
+    day 14 central thoracic tumor lesion define location involve abut hilar structure
+    presence central nodal disease allowed5 female subject pregnant breastfeeding6
+    receive potential inhibitor metabolism linifanib 21 day prior initial study drug
+    administration drug include cyp3a inhibitor eg triazole itraconazole ketoconazole
+    fluconazole grapefruit juice verapamil diltiazem aprepitant clarithromycin erythromycin
+    cyp1a2 inhibitor eg fluvoxamine ciprofloxacin mexiletine propafenone zileuton
+    cyp2c19 inhibitor eg omeprazole cyp2c8 substrate eg repaglinide paclitaxel rosiglitazone
+    cyp3a inducer eg rifampin carbamazepine7 proteinuria define national cancer institute
+    common terminology criterion adverse event nci ctcae grade   1 baseline measure
+    urine dipstick 2 great confirm 24 hour urine collection   1 g24 hrs subject rescreene
+    proteinuria show control intervention8 currently exhibit symptomatic persistent
+    uncontrolled hypertension define diastolic blood pressure bp   100 mmhg systolic
+    blood pressure bp   150 mmhg subject rescreene bp show control intervention9 clinically
+    significant uncontrolled condition include limit     active uncontrolled infection    class
+    iii iv heart failure define new york heart association functional classification
+    system    unstable angina pectoris cardiac arrhythmia    myocardial infarction
+    6 month    history adrenal insufficiency    history cerebral vascular accident
+    6 month    active ulcerative colitis crohns disease celiac disease condition interfere
+    absorption    history autoimmune disease kidney involvement    history overt bleeding   30
+    ml bleedingepisode 3 month study drug administration    psychiatric illnesssocial
+    situation limit compliance study requirement    medical condition opinion study
+    investigator place subject unacceptably high risk toxicities10 receive combination
+    antiretroviral therapy human immunodeficiency virus hiv11 consume grapefruit grapefruit
+    product 21 day prior initial study drug administration12 document leave ventricular
+    lv ejection fraction   50 investigate effect ketoconazole pharmacokinetic abt869
+    subject advanced metastatic solid tumor blood sample pk abt869 ketoconazole collect
+    designate time point study different timepoint day 112 safety adverse event   number
+    participant adverse event report measure safety adverse event monitor lab test
+    assessment physical exam vital sign evaluate study study
+- source_sentence: effect adhesive overlay delivery contraceptive hormone ortho evra
+    healthy woman. This is A Randomized, Blinded, Placebo- and Positive-Controlled,
+    Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect
+    of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
+  sentences:
+  - 'Alagille Syndrome inclusion criteria1 inform consent assent provide applicable
+    institutional review board irb ethic committee ec2 clinical andor genetic diagnosis
+    algs3 male female participant age 12 month 5 kg clinically significant cholestatic
+    pruritus associate algs4 willingness adhere acceptable method contraception treatment
+    discontinuation female childbeare potential sexually active sexually active program5
+    therapeutic option access ongoing algs clinical trialsexclusion criteria1 diagnosis
+    cholestatic liver disease algs2 female pregnant breastfeeding3 clinically significant
+    cardiovascular hepatic gastrointestinal pulmonary neurologic infectious renal
+    disease medical condition opinion physician medical monitor preclude participation
+    program4 past medical history compensate decompensate cirrhosis5 presence disease
+    condition know interfere absorption distribution metabolism excretion maralixibat
+    mode action  '
+  - Myopia|Refractive Error inclusion criterion willing able sign informed consent
+    document legal age consent legally authorize representative sign informed consent
+    document able achieve well correct visual acuity bcva 2025 snellen well eye distance
+    manifest cylinder equal 075 diopter eye wear contact lense protocoldefine specification
+    require spherical contact lense available range power protocoldefine inclusion
+    criterion applyexclusion criterion eye condition contraindicate contact lens wear
+    systemic ocular abnormality infection disease likely affect successful wear contact
+    lense use accessory solution moderate severe ocular finding examination use systemic
+    ocular medication contraindicate contact lens wear include use topical ocular
+    medication require instillation contact lens wear approve lubricating drop habitual
+    lense wear extended wear modality routinely sleep lense overnight 1 night week
+    3 month prior enrollment previous corneal refractive surgery irregular cornea
+    eye injury surgery 6 month exclude placement punctal plug monovision monocular
+    subject eye functional vision subject fit lens history intolerance hypersensitivity
+    component test article protocoldefine exclusion criterion apply subjective rating
+    overall satisfaction overall satisfaction rate participant 10point scale 1 dissatisfied
+    10 satisfied participant rate eye provide single rating day 7 positive purchase
+    intent report questionnaire response assume lense price expect pay likely purchase
+    lense binary positive vs negative response variable derive 5point likert scale
+    positive purchase intent report percentage participant choose definitely purchase
+    probably purchase day 7
+  - Healthy Volunteers inclusion criterion sign informed consent body mass index bmi
+    18 30 kgm2 inclusive body weight 50 kg 90 kg surgically sterile intact ovary abstinent
+    sexually active practice effective method nonhormonal birth control eg nonhormonal
+    intrauterine device doublebarrier method male partner sterilization entry study
+    complete term pregnancy 90 day admission study site history regular menstrual
+    cycle occur 25 35 day pregnant lactating blood pressure 90 140 mmhg systolic inclusive
+    high 90 mmhg diastolic hemoglobin equal 120 screeningexclusion criterion history
+    smoking use nicotinecontaine substance steroid hormonal therapy 30 day admission
+    study receive depo provera injection 6 month admission study history presence
+    disorder commonly accept contraindication sex hormonal therapy history current
+    clinically significant medical illness condition investigator consider exclude
+    patient interfere interpretation study result ngmn plasma concentration period
+    1 2 0 24 48 72 120 168 171 174 180 192 204 216 240 hoursee plasma concentration
+    period 1 2 0 24 48 72 120 168 171 174 180 192 204 216 240 hour pharmacokinetic
+    parameter ngmn period 1 2 pharmacokinetic parameter ngmn measure auc cmax tmax
+    css 0 24 48 72 120 168 171 174 180 192 204 216 240 hourspharmacokinetic parameter
+    ee period 1 2 pharmacokinetic parameter ee measure auc cmax tmax css 0 24 48 72
+    120 168 171 174 180 192 204 216 240 hoursincidence adverse event measure safety
+    tolerability approximately 2 monthsthe number patient change clinical laboratory
+    test value physical examination result vital sign measurement approximately 2
+    month
+- source_sentence: 'open label trial safety efficacy sym001 treatment immune thrombocytopenic
+    purpura itp. If your serious vaccine-induced adverse event has been entered in
+    the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling
+    you for this study in order to log your symptoms.
+
+
+    The primary goal of this study is to create a national database and gather vaccine-associated
+    serious adverse events/injury data from newly vaccinated individuals in the US
+    in order to identify the possible underlying causal relationships and plausible
+    underlying biological mechanisms. The project aims to identify the genetic determinants
+    of vaccine-induced adverse response by studying host genetics. We plan to use
+    whole genome sequencing to identify single nucleotide polymorphisms associated
+    with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological
+    symptoms induced by vaccine administration.
+
+
+    The secondary goal is to establish criteria that enable classification of vaccine-induced
+    adverse events/injuries compare data from our database with the official Vaccine
+    Injury Table National Vaccine Injury Compensation Program on or after March 21,
+    2017.
+
+
+    The tertiary goal is to establish a database to gather detailed long-term adverse
+    reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical
+    trials.'
+  sentences:
+  - Immune Thrombocytopenic Purpura inclusion criterion confirm presence thrombocytopenia
+    platelet count   30000mm3 predose visit history isolated itp rhdpositive serology
+    previous treatment response line therapy itpexclusion criterion know clinical
+    picture suggestive cause thrombocytopenia especially systematic lupus erythematosusantiphospholipid
+    syndrome evans syndrome immunodeficiency state lymphoproliferative disorder liver
+    diseaseingestion drug quinidinequinine heparin sulfonamide hereditary thrombocytopenia
+    confirm relevant laboratory finding suspect infection hiv hepatitis c h pylori
+    clinical splenomegaly history abnormal bone marrow examination ongoing haemorrhage
+    correspond grade 3 4 bleeding scale underlie haemolytic condition history splenectomy
+    subject pregnant breast feeding intend pregnant incidence severity adverse event
+    aes include adverse event saes 6 week post dose measurement platelet count day
+    1 week 6
+  - Type 2 Diabetes Mellitus inclusion criterion patient complete doubleblind base
+    study mk043106400nct00397631 75 compliance study medication base study treatment
+    period woman childbeare potential continue comply protocolspecifie contraceptive
+    method change baseline ie week 0 24week base study hemoglobin a1c hba1c week 54
+    hba1c measure percent change baseline reflect week 54 hba1c percent minus week
+    0 hba1c percent baseline 54 week change baseline ie week 0 24week base study fast
+    plasma glucose fpg week 54 change baseline week 54 define week 54 minus week 0
+    baseline week 54
+  - Multiple System Atrophy inclusion criteriadiagnostic1 participant diagnosis possible
+    probable msa modify gilman et al 2008 diagnostic criteria2 participant onset msa
+    symptom occur 4 year screen assess investigator3 evidence msa specific symptom
+    deficit measure umsars scaleexclusion criteriamedical history1 participant contraindication
+    study proceduresdiagnostic assessments1 presence confound diagnosis andor condition
+    affect participant safety study investigator judgement2 participant participation
+    previous study diseasemodifye therapy prove receipt active treatment compromise
+    interpretability datum present study consultation medical monitor designeeother1
+    participant participate study investigate active passive immunization αsynuclein
+    αsyn progressive disease pd msa immunoglobulin g therapy 6 month screen change
+    baseline modify unified multiple system atrophy rating scale umsar week 52 umsar
+    historical review 11item scale adapt unify parkinson disease rating scale updrs
+    assess activity relate motor disability relate autonomic dysfunction item score
+    0 normal 3 severe total score sum score domain range 0 33 high score mean poor
+    health 52 week change baseline 11item umsar week 52 11 item umsar include 11 item
+    ii assess motor autonomic disability umsar historical review assess activity relate
+    motor disability autonomic dysfunction umsar ii motor examination measure functional
+    impairment specific parkinsonian cerebellar feature item score 0 normal 4 severe
+    total score sum score domain range 0 44 high score mean poor health 52 weekschange
+    baseline umsar total score umsar   ii week 52 umsar total scale consist item umsars
+    part ii umsar historical review 12item scale assess activity relate motor disability
+    autonomic dysfunction item score 0 normal 4 severe umsar ii motor examination
+    14item scale measure functional impairment eg speech rapid alternate movement
+    hand finger tap leg agility select complex movement specific parkinsonian tremor
+    rest cerebellar ocular motor dysfunction heelshin test feature item score 0 normal
+    4 severe 52 weekschange baseline umsars week 52 umsar historical review modified
+    11item scale adapt updrs assess activity relate motor disability 8 item 4 novel
+    item relate autonomic dysfunction item score 0 normal 4 severe total score sum
+    score item range 0 44 high score mean poor health 52 weekschange baseline umsars
+    ii week 52 umsar ii motor examination 14item scale item eg speech rapid alternate
+    movement hand finger tap leg agility measure functional impairment select complex
+    movement item directly refer specific parkinsonian tremor rest cerebellar ocular
+    motor dysfunction heelshin test feature motor examination section umsar base modify
+    updrsiii item addition novel item heelkneeshin ataxia item score 0 normal 4 severe
+    total score sum score item range 0 56 high score mean poor health 52 weeksclinical
+    global impressionseverity cgis score cgis assess clinicians impression participant
+    clinical condition clinician use total clinical experience participant population
+    rate current severity participant illness 7point scale range 1 normal ill 7 extremely
+    ill participant high score mean well health 52 weekschange baseline scale outcome
+    parkinson disease   autonomic dysfunction scopaaut total score scopaaut patientreported
+    outcome assess autonomic function autonomic function critical symptom domain msa
+    scale selfcomplete participant consist 25 item assess follow domain gastrointestinal
+    7 item urinary 6 item cardiovascular 3 item thermoregulatory 4 item pupillomotor
+    1 item sexual 2 item man 2 item woman score item range 0 experience symptom 3
+    experience symptom total composite score include domain report score range 0 symptom
+    69 high burden symptom 52 weeksoverall survival os os define time day study drug
+    administration death cause 52 weekschange baseline level cerebrospinal fluid csf
+    free alphasynuclein αsyn 52 weekscmax maximum observe serum concentration tak341
+    predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57
+    85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortstmax
+    time occurrence cmax serum tak341 predose day 1 29 57 85 169 253 337 multiple
+    timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination
+    day 57 applicable early pk cohortsaucτ area concentrationtime curve dose interval
+    serum tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose
+    day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early
+    pk cohortscsf concentration tak341 lumbar puncture csf sampling perform predose
+    day 1 85 applicable early pk cohort 365number participant adverse event ae adverse
+    event ae define untoward medical occurrence participant administer pharmaceutical
+    product untoward medical occurrence necessarily causal relationship treatment
+    datum report number participant analyze safety parameter include clinically significant
+    abnormal value clinical laboratory evaluation vital sign ecg parameters physical
+    examination neurological examination columbiasuicide severity rating scale cssrs
+    52 weeksnumber participant antidrug antibody 52 week
+pipeline_tag: sentence-similarity
+library_name: sentence-transformers
 ---
+
+# SentenceTransformer based on sentence-transformers/all-MiniLM-L6-v2
+
+This is a [sentence-transformers](https://www.SBERT.net) model finetuned from [sentence-transformers/all-MiniLM-L6-v2](https://huggingface.co/sentence-transformers/all-MiniLM-L6-v2). It maps sentences & paragraphs to a 384-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.
+
+## Model Details
+
+### Model Description
+- **Model Type:** Sentence Transformer
+- **Base model:** [sentence-transformers/all-MiniLM-L6-v2](https://huggingface.co/sentence-transformers/all-MiniLM-L6-v2) <!-- at revision fa97f6e7cb1a59073dff9e6b13e2715cf7475ac9 -->
+- **Maximum Sequence Length:** 256 tokens
+- **Output Dimensionality:** 384 dimensions
+- **Similarity Function:** Cosine Similarity
+<!-- - **Training Dataset:** Unknown -->
+<!-- - **Language:** Unknown -->
+<!-- - **License:** Unknown -->
+
+### Model Sources
+
+- **Documentation:** [Sentence Transformers Documentation](https://sbert.net)
+- **Repository:** [Sentence Transformers on GitHub](https://github.com/UKPLab/sentence-transformers)
+- **Hugging Face:** [Sentence Transformers on Hugging Face](https://huggingface.co/models?library=sentence-transformers)
+
+### Full Model Architecture
+
+```
+SentenceTransformer(
+  (0): Transformer({'max_seq_length': 256, 'do_lower_case': False}) with Transformer model: BertModel 
+  (1): Pooling({'word_embedding_dimension': 384, 'pooling_mode_cls_token': False, 'pooling_mode_mean_tokens': True, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
+  (2): Normalize()
+)
+```
+
+## Usage
+
+### Direct Usage (Sentence Transformers)
+
+First install the Sentence Transformers library:
+
+```bash
+pip install -U sentence-transformers
+```
+
+Then you can load this model and run inference.
+```python
+from sentence_transformers import SentenceTransformer
+
+# Download from the 🤗 Hub
+model = SentenceTransformer("sentence_transformers_model_id")
+# Run inference
+sentences = [
+    'open label trial safety efficacy sym001 treatment immune thrombocytopenic purpura itp. If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.\n\nThe primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration.\n\nThe secondary goal is to establish criteria that enable classification of vaccine-induced adverse events/injuries compare data from our database with the official Vaccine Injury Table National Vaccine Injury Compensation Program on or after March 21, 2017.\n\nThe tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.',
+    'Immune Thrombocytopenic Purpura inclusion criterion confirm presence thrombocytopenia platelet count   30000mm3 predose visit history isolated itp rhdpositive serology previous treatment response line therapy itpexclusion criterion know clinical picture suggestive cause thrombocytopenia especially systematic lupus erythematosusantiphospholipid syndrome evans syndrome immunodeficiency state lymphoproliferative disorder liver diseaseingestion drug quinidinequinine heparin sulfonamide hereditary thrombocytopenia confirm relevant laboratory finding suspect infection hiv hepatitis c h pylori clinical splenomegaly history abnormal bone marrow examination ongoing haemorrhage correspond grade 3 4 bleeding scale underlie haemolytic condition history splenectomy subject pregnant breast feeding intend pregnant incidence severity adverse event aes include adverse event saes 6 week post dose measurement platelet count day 1 week 6',
+    'Multiple System Atrophy inclusion criteriadiagnostic1 participant diagnosis possible probable msa modify gilman et al 2008 diagnostic criteria2 participant onset msa symptom occur 4 year screen assess investigator3 evidence msa specific symptom deficit measure umsars scaleexclusion criteriamedical history1 participant contraindication study proceduresdiagnostic assessments1 presence confound diagnosis andor condition affect participant safety study investigator judgement2 participant participation previous study diseasemodifye therapy prove receipt active treatment compromise interpretability datum present study consultation medical monitor designeeother1 participant participate study investigate active passive immunization αsynuclein αsyn progressive disease pd msa immunoglobulin g therapy 6 month screen change baseline modify unified multiple system atrophy rating scale umsar week 52 umsar historical review 11item scale adapt unify parkinson disease rating scale updrs assess activity relate motor disability relate autonomic dysfunction item score 0 normal 3 severe total score sum score domain range 0 33 high score mean poor health 52 week change baseline 11item umsar week 52 11 item umsar include 11 item ii assess motor autonomic disability umsar historical review assess activity relate motor disability autonomic dysfunction umsar ii motor examination measure functional impairment specific parkinsonian cerebellar feature item score 0 normal 4 severe total score sum score domain range 0 44 high score mean poor health 52 weekschange baseline umsar total score umsar   ii week 52 umsar total scale consist item umsars part ii umsar historical review 12item scale assess activity relate motor disability autonomic dysfunction item score 0 normal 4 severe umsar ii motor examination 14item scale measure functional impairment eg speech rapid alternate movement hand finger tap leg agility select complex movement specific parkinsonian tremor rest cerebellar ocular motor dysfunction heelshin test feature item score 0 normal 4 severe 52 weekschange baseline umsars week 52 umsar historical review modified 11item scale adapt updrs assess activity relate motor disability 8 item 4 novel item relate autonomic dysfunction item score 0 normal 4 severe total score sum score item range 0 44 high score mean poor health 52 weekschange baseline umsars ii week 52 umsar ii motor examination 14item scale item eg speech rapid alternate movement hand finger tap leg agility measure functional impairment select complex movement item directly refer specific parkinsonian tremor rest cerebellar ocular motor dysfunction heelshin test feature motor examination section umsar base modify updrsiii item addition novel item heelkneeshin ataxia item score 0 normal 4 severe total score sum score item range 0 56 high score mean poor health 52 weeksclinical global impressionseverity cgis score cgis assess clinicians impression participant clinical condition clinician use total clinical experience participant population rate current severity participant illness 7point scale range 1 normal ill 7 extremely ill participant high score mean well health 52 weekschange baseline scale outcome parkinson disease   autonomic dysfunction scopaaut total score scopaaut patientreported outcome assess autonomic function autonomic function critical symptom domain msa scale selfcomplete participant consist 25 item assess follow domain gastrointestinal 7 item urinary 6 item cardiovascular 3 item thermoregulatory 4 item pupillomotor 1 item sexual 2 item man 2 item woman score item range 0 experience symptom 3 experience symptom total composite score include domain report score range 0 symptom 69 high burden symptom 52 weeksoverall survival os os define time day study drug administration death cause 52 weekschange baseline level cerebrospinal fluid csf free alphasynuclein αsyn 52 weekscmax maximum observe serum concentration tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortstmax time occurrence cmax serum tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortsaucτ area concentrationtime curve dose interval serum tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortscsf concentration tak341 lumbar puncture csf sampling perform predose day 1 85 applicable early pk cohort 365number participant adverse event ae adverse event ae define untoward medical occurrence participant administer pharmaceutical product untoward medical occurrence necessarily causal relationship treatment datum report number participant analyze safety parameter include clinically significant abnormal value clinical laboratory evaluation vital sign ecg parameters physical examination neurological examination columbiasuicide severity rating scale cssrs 52 weeksnumber participant antidrug antibody 52 week',
+]
+embeddings = model.encode(sentences)
+print(embeddings.shape)
+# [3, 384]
+
+# Get the similarity scores for the embeddings
+similarities = model.similarity(embeddings, embeddings)
+print(similarities.shape)
+# [3, 3]
+```
+
+<!--
+### Direct Usage (Transformers)
+
+<details><summary>Click to see the direct usage in Transformers</summary>
+
+</details>
+-->
+
+<!--
+### Downstream Usage (Sentence Transformers)
+
+You can finetune this model on your own dataset.
+
+<details><summary>Click to expand</summary>
+
+</details>
+-->
+
+<!--
+### Out-of-Scope Use
+
+*List how the model may foreseeably be misused and address what users ought not to do with the model.*
+-->
+
+<!--
+## Bias, Risks and Limitations
+
+*What are the known or foreseeable issues stemming from this model? You could also flag here known failure cases or weaknesses of the model.*
+-->
+
+<!--
+### Recommendations
+
+*What are recommendations with respect to the foreseeable issues? For example, filtering explicit content.*
+-->
+
+## Training Details
+
+### Training Dataset
+
+#### Unnamed Dataset
+
+
+* Size: 92,934 training samples
+* Columns: <code>Text1</code> and <code>Text2</code>
+* Approximate statistics based on the first 1000 samples:
+  |         | Text1                                                                                | Text2                                                                               |
+  |:--------|:-------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------|
+  | type    | string                                                                               | string                                                                              |
+  | details | <ul><li>min: 29 tokens</li><li>mean: 104.36 tokens</li><li>max: 256 tokens</li></ul> | <ul><li>min: 8 tokens</li><li>mean: 227.98 tokens</li><li>max: 256 tokens</li></ul> |
+* Samples:
+  | Text1                                                                                                                                                                                                                                                                                                                               | Text2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
+  |:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
+  | <code>study people normal kidney function people reduce kidney function test bi 1467335 process body. The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.</code> | <code>Renal Insufficiency|Healthy inclusion criterion despite moderate renal impairment group 1 healthy male female subject accord assessment investigator base complete medical history include physical examination vital sign blood pressure bp pulse rate pr 12lead electrocardiogram ecg clinical laboratory test estimate glomerular filtration rate egfr base ckdepi formula group 1 30 59 mlmin173m2 group 2   90 mlmin173m2 age 18 79 year incl bmi 185 34 kgm2 incl sign date write inform consent prior admission study accordance good clinical practice gcp local legislation male subject female subject meet follow criterion accord ctfg recommendation relate contraception pregnancy testing clinical trial method failure rate 1 year start 30 day administration trial medication 30 day trial completion eg    use adequate contraception eg follow method plus condom implant injectable combine oral vaginal contraceptive inhibition ovulation   hormonal intrauterine device   sexually abstinent define refrain hete...</code> |
+  | <code>16w interventional study titration doseefficacy assessment exelon chinese alzheimers disease patient. To investigate the efficacy of Exelon capsule at maximal tolerated dose in mild to moderate Chinese AD patients via dosage titration from 3mg/d to 12mg/d in a 16 weeks duration</code>                                 | <code>Alzheimer's Disease key inclusion criterion diagnosis dementia alzheimers type accord dsmiv criterion clinical diagnosis probable ad accord nincdsadrda criteria mmse score   10   26 treatment naïve patient stop donepezil galantamine huperzine memantine 2 week stable medical condition sign inform consent form patient hisher legal guardiankey exclusion criterion severe ad patient history cerebrovascular disease active uncontrolled epilepsy active hypothyroidism asthma cns infection neurodegenerative disorder advanced severe progressive unstable medical condition attend clinical trial take clinical trial drug score   4 modify hachinski ischemic scale mhis patient achei memantine mean change baseline alzheimer disease assessment scale   cognitive subscale adascog alzheimer disease assessment scale   cognitive subscale adascog measure change cognitive function alzheimer disease assessment scale adas scale measure specific cognitive behavior disorder alzheimer disease ad patient alzheimer di...</code> |
+  | <code>case series saneso 360 gastroscope. To confirm the procedural performance of the Saneso 360° gastroscope in Esophago-gastro-duodenoscopy (EGD) procedures.</code>                                                                                                                                                             | <code>EGD Procedure inclusion criterion 18 74 year age willing able comply study procedure provide write inform consent participate study schedule clinically indicate routine egd procedure asa class 13exclusion criterion alter esophageal gastric duodenal anatomy pregnant woman child 18 year age adult 75 year age subject routine endoscopic procedure contraindicate comorbid medical condition patient currently enrol investigational study directly interfere current study prior write approval sponsor asa class 45 successful egd procedure success assess end procedure 1 procedure success define successful intubation portion duodenum photograph portion duodenum take 24 hour study day endoscopist qualitative rating saneso 360 gastroscope endoscopist rate experience saneso 360 gastroscope immediately follow completion study procedure 1 fivepoint likert scale 5   excellent 4   good 3 acceptable 2 difficult 1unacceptable 24 hour study dayendoscopist qualitative rating saneso 360 gastroscope compare past...</code> |
+* Loss: [<code>MatryoshkaLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#matryoshkaloss) with these parameters:
+  ```json
+  {
+      "loss": "MultipleNegativesRankingLoss",
+      "matryoshka_dims": [
+          384,
+          256,
+          128,
+          64
+      ],
+      "matryoshka_weights": [
+          1,
+          1,
+          1,
+          1
+      ],
+      "n_dims_per_step": -1
+  }
+  ```
+
+### Training Hyperparameters
+#### Non-Default Hyperparameters
+
+- `per_device_train_batch_size`: 16
+- `learning_rate`: 2e-05
+- `num_train_epochs`: 1
+- `warmup_ratio`: 0.1
+- `fp16`: True
+- `batch_sampler`: no_duplicates
+
+#### All Hyperparameters
+<details><summary>Click to expand</summary>
+
+- `overwrite_output_dir`: False
+- `do_predict`: False
+- `eval_strategy`: no
+- `prediction_loss_only`: True
+- `per_device_train_batch_size`: 16
+- `per_device_eval_batch_size`: 8
+- `per_gpu_train_batch_size`: None
+- `per_gpu_eval_batch_size`: None
+- `gradient_accumulation_steps`: 1
+- `eval_accumulation_steps`: None
+- `torch_empty_cache_steps`: None
+- `learning_rate`: 2e-05
+- `weight_decay`: 0.0
+- `adam_beta1`: 0.9
+- `adam_beta2`: 0.999
+- `adam_epsilon`: 1e-08
+- `max_grad_norm`: 1.0
+- `num_train_epochs`: 1
+- `max_steps`: -1
+- `lr_scheduler_type`: linear
+- `lr_scheduler_kwargs`: {}
+- `warmup_ratio`: 0.1
+- `warmup_steps`: 0
+- `log_level`: passive
+- `log_level_replica`: warning
+- `log_on_each_node`: True
+- `logging_nan_inf_filter`: True
+- `save_safetensors`: True
+- `save_on_each_node`: False
+- `save_only_model`: False
+- `restore_callback_states_from_checkpoint`: False
+- `no_cuda`: False
+- `use_cpu`: False
+- `use_mps_device`: False
+- `seed`: 42
+- `data_seed`: None
+- `jit_mode_eval`: False
+- `use_ipex`: False
+- `bf16`: False
+- `fp16`: True
+- `fp16_opt_level`: O1
+- `half_precision_backend`: auto
+- `bf16_full_eval`: False
+- `fp16_full_eval`: False
+- `tf32`: None
+- `local_rank`: 0
+- `ddp_backend`: None
+- `tpu_num_cores`: None
+- `tpu_metrics_debug`: False
+- `debug`: []
+- `dataloader_drop_last`: False
+- `dataloader_num_workers`: 0
+- `dataloader_prefetch_factor`: None
+- `past_index`: -1
+- `disable_tqdm`: False
+- `remove_unused_columns`: True
+- `label_names`: None
+- `load_best_model_at_end`: False
+- `ignore_data_skip`: False
+- `fsdp`: []
+- `fsdp_min_num_params`: 0
+- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
+- `fsdp_transformer_layer_cls_to_wrap`: None
+- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
+- `deepspeed`: None
+- `label_smoothing_factor`: 0.0
+- `optim`: adamw_torch
+- `optim_args`: None
+- `adafactor`: False
+- `group_by_length`: False
+- `length_column_name`: length
+- `ddp_find_unused_parameters`: None
+- `ddp_bucket_cap_mb`: None
+- `ddp_broadcast_buffers`: False
+- `dataloader_pin_memory`: True
+- `dataloader_persistent_workers`: False
+- `skip_memory_metrics`: True
+- `use_legacy_prediction_loop`: False
+- `push_to_hub`: False
+- `resume_from_checkpoint`: None
+- `hub_model_id`: None
+- `hub_strategy`: every_save
+- `hub_private_repo`: None
+- `hub_always_push`: False
+- `gradient_checkpointing`: False
+- `gradient_checkpointing_kwargs`: None
+- `include_inputs_for_metrics`: False
+- `include_for_metrics`: []
+- `eval_do_concat_batches`: True
+- `fp16_backend`: auto
+- `push_to_hub_model_id`: None
+- `push_to_hub_organization`: None
+- `mp_parameters`: 
+- `auto_find_batch_size`: False
+- `full_determinism`: False
+- `torchdynamo`: None
+- `ray_scope`: last
+- `ddp_timeout`: 1800
+- `torch_compile`: False
+- `torch_compile_backend`: None
+- `torch_compile_mode`: None
+- `dispatch_batches`: None
+- `split_batches`: None
+- `include_tokens_per_second`: False
+- `include_num_input_tokens_seen`: False
+- `neftune_noise_alpha`: None
+- `optim_target_modules`: None
+- `batch_eval_metrics`: False
+- `eval_on_start`: False
+- `use_liger_kernel`: False
+- `eval_use_gather_object`: False
+- `average_tokens_across_devices`: False
+- `prompts`: None
+- `batch_sampler`: no_duplicates
+- `multi_dataset_batch_sampler`: proportional
+
+</details>
+
+### Training Logs
+| Epoch  | Step | Training Loss |
+|:------:|:----:|:-------------:|
+| 0.0861 | 500  | 2.1564        |
+| 0.1721 | 1000 | 1.6731        |
+| 0.2582 | 1500 | 1.3615        |
+| 0.3443 | 2000 | 1.331         |
+| 0.4304 | 2500 | 1.2666        |
+| 0.5164 | 3000 | 1.1645        |
+| 0.6025 | 3500 | 1.159         |
+| 0.6886 | 4000 | 1.0752        |
+| 0.7747 | 4500 | 1.0458        |
+| 0.8607 | 5000 | 1.0803        |
+| 0.9468 | 5500 | 1.0237        |
+
+
+### Framework Versions
+- Python: 3.10.12
+- Sentence Transformers: 3.3.1
+- Transformers: 4.48.1
+- PyTorch: 2.1.0a0+32f93b1
+- Accelerate: 1.3.0
+- Datasets: 3.2.0
+- Tokenizers: 0.21.0
+
+## Citation
+
+### BibTeX
+
+#### Sentence Transformers
+```bibtex
+@inproceedings{reimers-2019-sentence-bert,
+    title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
+    author = "Reimers, Nils and Gurevych, Iryna",
+    booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
+    month = "11",
+    year = "2019",
+    publisher = "Association for Computational Linguistics",
+    url = "https://arxiv.org/abs/1908.10084",
+}
+```
+
+#### MatryoshkaLoss
+```bibtex
+@misc{kusupati2024matryoshka,
+    title={Matryoshka Representation Learning},
+    author={Aditya Kusupati and Gantavya Bhatt and Aniket Rege and Matthew Wallingford and Aditya Sinha and Vivek Ramanujan and William Howard-Snyder and Kaifeng Chen and Sham Kakade and Prateek Jain and Ali Farhadi},
+    year={2024},
+    eprint={2205.13147},
+    archivePrefix={arXiv},
+    primaryClass={cs.LG}
+}
+```
+
+#### MultipleNegativesRankingLoss
+```bibtex
+@misc{henderson2017efficient,
+    title={Efficient Natural Language Response Suggestion for Smart Reply},
+    author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
+    year={2017},
+    eprint={1705.00652},
+    archivePrefix={arXiv},
+    primaryClass={cs.CL}
+}
+```
+
+<!--
+## Glossary
+
+*Clearly define terms in order to be accessible across audiences.*
+-->
+
+<!--
+## Model Card Authors
+
+*Lists the people who create the model card, providing recognition and accountability for the detailed work that goes into its construction.*
+-->
+
+<!--
+## Model Card Contact
+
+*Provides a way for people who have updates to the Model Card, suggestions, or questions, to contact the Model Card authors.*
+-->

config.json

@@ -0,0 +1,26 @@
+{
+  "_name_or_path": "model/checkpoint-5809",
+  "architectures": [
+    "BertModel"
+  ],
+  "attention_probs_dropout_prob": 0.1,
+  "classifier_dropout": null,
+  "gradient_checkpointing": false,
+  "hidden_act": "gelu",
+  "hidden_dropout_prob": 0.1,
+  "hidden_size": 384,
+  "initializer_range": 0.02,
+  "intermediate_size": 1536,
+  "layer_norm_eps": 1e-12,
+  "max_position_embeddings": 512,
+  "model_type": "bert",
+  "num_attention_heads": 12,
+  "num_hidden_layers": 6,
+  "pad_token_id": 0,
+  "position_embedding_type": "absolute",
+  "torch_dtype": "float32",
+  "transformers_version": "4.46.3",
+  "type_vocab_size": 2,
+  "use_cache": true,
+  "vocab_size": 30522
+}

config_sentence_transformers.json

@@ -0,0 +1,10 @@
+{
+  "__version__": {
+    "sentence_transformers": "3.3.1",
+    "transformers": "4.46.3",
+    "pytorch": "2.5.1+cpu"
+  },
+  "prompts": {},
+  "default_prompt_name": null,
+  "similarity_fn_name": "cosine"
+}

modules.json

@@ -0,0 +1,20 @@
+[
+  {
+    "idx": 0,
+    "name": "0",
+    "path": "",
+    "type": "sentence_transformers.models.Transformer"
+  },
+  {
+    "idx": 1,
+    "name": "1",
+    "path": "1_Pooling",
+    "type": "sentence_transformers.models.Pooling"
+  },
+  {
+    "idx": 2,
+    "name": "2",
+    "path": "2_Normalize",
+    "type": "sentence_transformers.models.Normalize"
+  }
+]

sentence_bert_config.json

@@ -0,0 +1,4 @@
+{
+  "max_seq_length": 256,
+  "do_lower_case": false
+}

special_tokens_map.json

@@ -0,0 +1,37 @@
+{
+  "cls_token": {
+    "content": "[CLS]",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "mask_token": {
+    "content": "[MASK]",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "pad_token": {
+    "content": "[PAD]",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "sep_token": {
+    "content": "[SEP]",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "unk_token": {
+    "content": "[UNK]",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  }
+}

tokenizer_config.json

@@ -0,0 +1,65 @@
+{
+  "added_tokens_decoder": {
+    "0": {
+      "content": "[PAD]",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "100": {
+      "content": "[UNK]",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "101": {
+      "content": "[CLS]",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "102": {
+      "content": "[SEP]",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "103": {
+      "content": "[MASK]",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    }
+  },
+  "clean_up_tokenization_spaces": false,
+  "cls_token": "[CLS]",
+  "do_basic_tokenize": true,
+  "do_lower_case": true,
+  "extra_special_tokens": {},
+  "mask_token": "[MASK]",
+  "max_length": 128,
+  "model_max_length": 256,
+  "never_split": null,
+  "pad_to_multiple_of": null,
+  "pad_token": "[PAD]",
+  "pad_token_type_id": 0,
+  "padding_side": "right",
+  "sep_token": "[SEP]",
+  "stride": 0,
+  "strip_accents": null,
+  "tokenize_chinese_chars": true,
+  "tokenizer_class": "BertTokenizer",
+  "truncation_side": "right",
+  "truncation_strategy": "longest_first",
+  "unk_token": "[UNK]"
+}